{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T10:07:17Z","timestamp":1792145237792,"version":"4.4.0"},"reference-count":98,"publisher":"Japan Neurosurgical Society","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neurol. Med. Chir.(Tokyo)"],"published-print":{"date-parts":[[2017]]},"DOI":"10.2176\/nmc.ra.2017-0018","type":"journal-article","created":{"date-parts":[[2017,6,6]],"date-time":"2017-06-06T22:09:40Z","timestamp":1496786980000},"page":"331-342","source":"Crossref","is-referenced-by-count":46,"title":["Epigenetic Targeted Therapy for Diffuse Intrinsic Pontine Glioma"],"prefix":"10.2176","volume":"57","author":[{"given":"Rintaro","family":"HASHIZUME","sequence":"first","affiliation":[{"name":"Department of Neurological Surgery, Northwestern University"},{"name":"Department of Biochemistry and Molecular Genetics, Northwestern University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"971","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Wong ET, Hess KR, Gleason MJ, et al.: Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. <i>J Clin Oncol<\/i> 17: 2572\u20132578, 1999","DOI":"10.1200\/JCO.1999.17.8.2572"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Buckner JC: Factors influencing survival in high-grade gliomas. <i>Semin Oncol<\/i> 30: 10\u201314, 2003","DOI":"10.1053\/j.seminoncol.2003.11.031"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Louis DN, Ohgaki H, Wiestler OD, et al.: The 2007 WHO classification of tumours of the central nervous system. <i>Acta Neuropathol<\/i> 114: 97\u2013109, 2007","DOI":"10.1007\/s00401-007-0243-4"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Freeman CR, Farmer JP: Pediatric brain stem gliomas: a review. <i>Int J Radiat Oncol Biol Phys<\/i> 40: 265\u2013271, 1998","DOI":"10.1016\/S0360-3016(97)00572-5"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Berger MS, Edwards MS, LaMasters D, Davis RL, Wilson CB: Pediatric brain stem tumors: radiographic, pathological, and clinical correlations. <i>Neurosurgery<\/i> 12: 298\u2013302, 1983","DOI":"10.1097\/00006123-198303000-00008"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Littman P, Jarrett P, Bilaniuk LT, et al.: Pediatric brain stem gliomas. <i>Cancer<\/i> 45: 2787\u20132792, 1980","DOI":"10.1002\/1097-0142(19800601)45:11<2787::AID-CNCR2820451113>3.0.CO;2-V"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Hargrave D, Bartels U, Bouffet E: Diffuse brainstem glioma in children: critical review of clinical trials. <i>Lancet Oncol<\/i> 7: 241\u2013248, 2006","DOI":"10.1016\/S1470-2045(06)70615-5"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Donaldson SS, Laningham F, Fisher PG: Advances toward an understanding of brainstem gliomas. <i>J Clin Oncol<\/i> 24: 1266\u20131272, 2006","DOI":"10.1200\/JCO.2005.04.6599"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Frazier JL, Lee J, Thomale UW, Noggle JC, Cohen KJ, Jallo GI: Treatment of diffuse intrinsic brainstem gliomas: failed approaches and future strategies. <i>J Neurosurg Pediatr<\/i> 3: 259\u2013269, 2009","DOI":"10.3171\/2008.11.PEDS08281"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Robison NJ, Kieran MW: Diffuse intrinsic pontine glioma: a reassessment. <i>J Neurooncol<\/i> 119: 7\u201315, 2014","DOI":"10.1007\/s11060-014-1448-8"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Roos DE, Smith JG: Randomized trial on radiotherapy for paediatric diffuse intrinsic pontine glioma (DIPG). <i>Radiother Oncol<\/i> 113: 425, 2014","DOI":"10.1016\/j.radonc.2014.08.041"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Warren KE: Diffuse intrinsic pontine glioma: poised for progress. <i>Front Oncol<\/i> 2: 205, 2012","DOI":"10.3389\/fonc.2012.00205"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Fangusaro J: Pediatric high-grade gliomas and diffuse intrinsic pontine gliomas. <i>J Child Neurol<\/i> 24: 1409\u20131417, 2009","DOI":"10.1177\/0883073809338960"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Kebudi R, Cakir FB: Management of diffuse pontine gliomas in children: recent developments. <i>Paediatr Drugs<\/i> 15: 351\u2013362, 2013","DOI":"10.1007\/s40272-013-0033-5"},{"key":"15","unstructured":"15) Barkovich AJ, Krischer J, Kun LE, et al.: Brain stem gliomas: a classification system based on magnetic resonance imaging. <i>Pediatr Neurosurg<\/i> 16: 73\u201383, 1990"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Roujeau T, Machado G, Garnett MR, et al.: Stereotactic biopsy of diffuse pontine lesions in children. <i>J Neurosurg<\/i> 107: 1\u20134, 2007","DOI":"10.3171\/PED-07\/07\/001"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Puget S, Philippe C, Bax DA, et al.: Mesenchymal transition and PDGFRA amplification\/mutation are key distinct oncogenic events in pediatric diffuse intrinsic pontine gliomas. <i>PLoS One<\/i> 7: e30313, 2012","DOI":"10.1371\/journal.pone.0030313"},{"key":"18","unstructured":"18) Geoerger B, Hargrave D, Thomas F, et al.: ITCC (Innovative Therapies for Children with Cancer) European Consortium: Innovative Therapies for Children with Cancer pediatric phase I study of erlotinib in brainstem glioma and relapsing\/refractory brain tumors. <i>Neuro-oncology<\/i> 13: 109\u2013118, 2011"},{"key":"19","unstructured":"19) Fontebasso AM, Papillon-Cavanagh S, Schwartzentruber J, et al.: Recurrent somatic mutations in ACVR1 in pediatric midline high-grade astrocytoma. <i>Nat Genet<\/i> 46: 462\u2013466, 2014"},{"key":"20","unstructured":"20) Schwartzentruber J, Korshunov A, Liu XY, et al.: Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. <i>Nature<\/i> 482: 226\u2013231, 2012"},{"key":"21","unstructured":"21) Wu G, Broniscer A, McEachron TA, et al.: St. Jude Children\u2019s Research Hospital\u2013Washington University Pediatric Cancer Genome Project: Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. <i>Nat Genet<\/i> 44: 251\u2013253, 2012"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Chan KM, Fang D, Gan H, et al.: The histone H3.3K27M mutation in pediatric glioma reprograms H3K27 methylation and gene expression. <i>Genes Dev<\/i> 27: 985\u2013990, 2013","DOI":"10.1101\/gad.217778.113"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Lewis PW, M\u00fcller MM, Koletsky MS, et al.: Inhibition of PRC2 activity by a gain-of-function H3 mutation found in pediatric glioblastoma. <i>Science<\/i> 340: 857\u2013861, 2013","DOI":"10.1126\/science.1232245"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Bender S, Tang Y, Lindroth AM, et al.: Reduced H3K27me3 and DNA hypomethylation are major drivers of gene expression in K27M mutant pediatric high-grade gliomas. <i>Cancer Cell<\/i> 24: 660\u2013672, 2013","DOI":"10.1016\/j.ccr.2013.10.006"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Venneti S, Garimella MT, Sullivan LM, et al.: Evaluation of histone 3 lysine 27 trimethylation (H3K27me3) and enhancer of Zest 2 (EZH2) in pediatric glial and glioneuronal tumors shows decreased H3K27me3 in H3F3A K27M mutant glioblastomas. <i>Brain Pathol<\/i> 23: 558\u2013564, 2013","DOI":"10.1111\/bpa.12042"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Hashizume R, Andor N, Ihara Y, et al.: Pharmacologic inhibition of histone demethylation as a therapy for pediatric brainstem glioma. <i>Nat Med<\/i> 20: 1394\u20131396, 2014","DOI":"10.1038\/nm.3716"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Khuong-Quang DA, Buczkowicz P, Rakopoulos P, et al.: K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas. <i>Acta Neuropathol<\/i> 124: 439\u2013447, 2012","DOI":"10.1007\/s00401-012-0998-0"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Churchman LS, Weissman JS: Nascent transcript sequencing visualizes transcription at nucleotide resolution. <i>Nature<\/i> 469: 368\u2013373, 2011","DOI":"10.1038\/nature09652"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Hodges C, Bintu L, Lubkowska L, Kashlev M, Bustamante C: Nucleosomal fluctuations govern the transcription dynamics of RNA polymerase II. <i>Science<\/i> 325: 626\u2013628, 2009","DOI":"10.1126\/science.1172926"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Furey TS, Sethupathy P: Genetics. Genetics driving epigenetics. <i>Science<\/i> 342: 705\u2013706, 2013","DOI":"10.1126\/science.1246755"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Strahl BD, Allis CD: The language of covalent histone modifications. <i>Nature<\/i> 403: 41\u201345, 2000","DOI":"10.1038\/47412"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Henikoff S: Nucleosome destabilization in the epigenetic regulation of gene expression. <i>Nat Rev Genet<\/i> 9: 15\u201326, 2008","DOI":"10.1038\/nrg2206"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Rivera CM, Ren B: Mapping human epigenomes. <i>Cell<\/i> 155: 39\u201355, 2013","DOI":"10.1016\/j.cell.2013.09.011"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Bird A: Perceptions of epigenetics. <i>Nature<\/i> 447: 396\u2013398, 2007","DOI":"10.1038\/nature05913"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Kaelin WG, McKnight SL: Influence of metabolism on epigenetics and disease. <i>Cell<\/i> 153: 56\u201369, 2013","DOI":"10.1016\/j.cell.2013.03.004"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36) Black JC, Van Rechem C, Whetstine JR: Histone lysine methylation dynamics: establishment, regulation, and biological impact. <i>Mol Cell<\/i> 48: 491\u2013507, 2012","DOI":"10.1016\/j.molcel.2012.11.006"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37) Arcipowski KM, Martinez CA, Ntziachristos P: Histone demethylases in physiology and cancer: a tale of two enzymes, JMJD3 and UTX. <i>Curr Opin Genet Dev<\/i> 36: 59\u201367, 2016","DOI":"10.1016\/j.gde.2016.03.010"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38) Wang Z, Zang C, Cui K, et al.: Genome-wide mapping of HATs and HDACs reveals distinct functions in active and inactive genes. <i>Cell<\/i> 138: 1019\u20131031, 2009","DOI":"10.1016\/j.cell.2009.06.049"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39) Filippakopoulos P, Knapp S: Targeting bromodomains: epigenetic readers of lysine acetylation. <i>Nat Rev Drug Discov<\/i> 13: 337\u2013356, 2014","DOI":"10.1038\/nrd4286"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40) Herz HM, Morgan M, Gao X, et al.: Histone H3 lysine-to-methionine mutants as a paradigm to study chromatin signaling. <i>Science<\/i> 345: 1065\u20131070, 2014","DOI":"10.1126\/science.1255104"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41) Lin CY, Erkek S, Tong Y, et al.: Active medulloblastoma enhancers reveal subgroup-specific cellular origins. <i>Nature<\/i> 530: 57\u201362, 2016","DOI":"10.1038\/nature16546"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42) Wadhwa E, Nicolaides T: Bromodomain Inhibitor Review: Bromodomain and Extra-terminal Family Protein Inhibitors as a Potential New Therapy in Central Nervous System Tumors. <i>Cureus<\/i> 8: e620, 2016","DOI":"10.7759\/cureus.620"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43) Piunti A, Hashizume R, Morgan MA, et al.: Therapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas. <i>Nat Med<\/i> 23: 493\u2013500, 2017","DOI":"10.1038\/nm.4296"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44) Barski A, Cuddapah S, Cui K, et al.: High-resolution profiling of histone methylations in the human genome. <i>Cell<\/i> 129: 823\u2013837, 2007","DOI":"10.1016\/j.cell.2007.05.009"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45) Heintzman ND, Hon GC, Hawkins RD, et al.: Histone modifications at human enhancers reflect global cell-type-specific gene expression. <i>Nature<\/i> 459: 108\u2013112, 2009","DOI":"10.1038\/nature07829"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46) M\u00fcller J, Hart CM, Francis NJ, et al.: Histone methyltransferase activity of a Drosophila Polycomb group repressor complex. <i>Cell<\/i> 111: 197\u2013208, 2002","DOI":"10.1016\/S0092-8674(02)00976-5"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47) Czermin B, Melfi R, McCabe D, Seitz V, Imhof A, Pirrotta V: Drosophila enhancer of Zeste\/ESC complexes have a histone H3 methyltransferase activity that marks chromosomal Polycomb sites. <i>Cell<\/i> 111: 185\u2013196, 2002","DOI":"10.1016\/S0092-8674(02)00975-3"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48) Ezponda T, Licht JD: Molecular pathways: deregulation of histone h3 lysine 27 methylation in cancer-different paths, same destination. <i>Clin Cancer Res<\/i> 20: 5001\u20135008, 2014","DOI":"10.1158\/1078-0432.CCR-13-2499"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49) Agger K, Cloos PA, Christensen J, et al.: UTX and JMJD3 are histone H3K27 demethylases involved in HOX gene regulation and development. <i>Nature<\/i> 449: 731\u2013734, 2007","DOI":"10.1038\/nature06145"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50) Deb G, Singh AK, Gupta S: EZH2: not EZHY (easy) to deal. <i>Mol Cancer Res<\/i> 12: 639\u2013653, 2014","DOI":"10.1158\/1541-7786.MCR-13-0546"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51) Simon JA, Lange CA: Roles of the EZH2 histone methyltransferase in cancer epigenetics. <i>Mutat Res<\/i> 647: 21\u201329, 2008","DOI":"10.1016\/j.mrfmmm.2008.07.010"},{"key":"52","doi-asserted-by":"crossref","unstructured":"52) Kleer CG, Cao Q, Varambally S, et al.: EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. <i>Proc Natl Acad Sci USA<\/i> 100: 11606\u201311611, 2003","DOI":"10.1073\/pnas.1933744100"},{"key":"53","doi-asserted-by":"crossref","unstructured":"53) Varambally S, Dhanasekaran SM, Zhou M, et al.: The polycomb group protein EZH2 is involved in progression of prostate cancer. <i>Nature<\/i> 419: 624\u2013629, 2002","DOI":"10.1038\/nature01075"},{"key":"54","doi-asserted-by":"crossref","unstructured":"54) H\u00fcbner MR, Spector DL: Role of H3K27 demethylases Jmjd3 and UTX in transcriptional regulation. <i>Cold Spring Harb Symp Quant Biol<\/i> 75: 43\u201349, 2010","DOI":"10.1101\/sqb.2010.75.020r"},{"key":"55","doi-asserted-by":"crossref","unstructured":"55) Kooistra SM, Helin K: Molecular mechanisms and potential functions of histone demethylases. <i>Nat Rev Mol Cell Biol<\/i> 13: 297\u2013311, 2012","DOI":"10.1038\/nrm3327"},{"key":"56","doi-asserted-by":"crossref","unstructured":"56) Cloos PA, Christensen J, Agger K, Helin K: Erasing the methyl mark: histone demethylases at the center of cellular differentiation and disease. <i>Genes Dev<\/i> 22: 1115\u20131140, 2008","DOI":"10.1101\/gad.1652908"},{"key":"57","unstructured":"57) Jones DT, J\u00e4ger N, Kool M, et al.: Dissecting the genomic complexity underlying medulloblastoma. <i>Nature<\/i> 488: 100\u2013105, 2012"},{"key":"58","doi-asserted-by":"crossref","unstructured":"58) Ntziachristos P, Tsirigos A, Van Vlierberghe P, et al.: Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia. <i>Nat Med<\/i> 18: 298\u2013301, 2012","DOI":"10.1038\/nm.2651"},{"key":"59","unstructured":"59) Pugh TJ, Weeraratne SD, Archer TC, et al.: Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations. <i>Nature<\/i> 488: 106\u2013110, 2012"},{"key":"60","doi-asserted-by":"crossref","unstructured":"60) Imielinski M, Berger AH, Hammerman PS, et al.: Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. <i>Cell<\/i> 150: 1107\u20131120, 2012","DOI":"10.1016\/j.cell.2012.08.029"},{"key":"61","doi-asserted-by":"crossref","unstructured":"61) Martinez-Garcia E, Licht JD: Deregulation of H3K27 methylation in cancer. <i>Nat Genet<\/i> 42: 100\u2013101, 2010","DOI":"10.1038\/ng0210-100"},{"key":"62","unstructured":"62) Sturm D, Witt H, Hovestadt V, et al.: Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. <i>Cancer Cell<\/i> 22: 425\u2013437, 2012"},{"key":"63","unstructured":"63) Buczkowicz P, Hoeman C, Rakopoulos P, et al.: Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutations. <i>Nat Genet<\/i> 46: 451\u2013456, 2014"},{"key":"64","doi-asserted-by":"crossref","unstructured":"64) Waldmann T, Schneider R: Targeting histone modifications\u2014epigenetics in cancer. <i>Curr Opin Cell Biol<\/i> 25: 184\u2013189, 2013","DOI":"10.1016\/j.ceb.2013.01.001"},{"key":"65","doi-asserted-by":"crossref","unstructured":"65) Taylor KR, Mackay A, Truffaux N, et al.: Recurrent activating ACVR1 mutations in diffuse intrinsic pontine glioma. <i>Nat Genet<\/i> 46: 457\u2013461, 2014","DOI":"10.1038\/ng.2925"},{"key":"66","unstructured":"66) Sturm D, Bender S, Jones DT, et al.: Paediatric and adult glioblastoma: multiform (epi)genomic culprits emerge. <i>Nat Rev Cancer<\/i> 14: 92\u2013107, 2014"},{"key":"67","doi-asserted-by":"crossref","unstructured":"67) Zadeh G, Aldape K: ACVR1 mutations and the genomic landscape of pediatric diffuse glioma. <i>Nat Genet<\/i> 46: 421\u2013422, 2014","DOI":"10.1038\/ng.2970"},{"key":"68","doi-asserted-by":"crossref","unstructured":"68) Funato K, Major T, Lewis PW, Allis CD, Tabar V: Use of human embryonic stem cells to model pediatric gliomas with H3.3K27M histone mutation. <i>Science<\/i> 346: 1529\u20131533, 2014","DOI":"10.1126\/science.1253799"},{"key":"69","doi-asserted-by":"crossref","unstructured":"69) Bax DA, Mackay A, Little SE, et al.: A distinct spectrum of copy number aberrations in pediatric high-grade gliomas. <i>Clin Cancer Res<\/i> 16: 3368\u20133377, 2010","DOI":"10.1158\/1078-0432.CCR-10-0438"},{"key":"70","doi-asserted-by":"crossref","unstructured":"70) Paugh BS, Qu C, Jones C, et al.: Integrated molecular genetic profiling of pediatric high-grade gliomas reveals key differences with the adult disease. <i>J Clin Oncol<\/i> 28: 3061\u20133068, 2010","DOI":"10.1200\/JCO.2009.26.7252"},{"key":"71","doi-asserted-by":"crossref","unstructured":"71) Becher OJ, Wechsler-Reya RJ: Cancer. For pediatric glioma, leave no histone unturned. <i>Science<\/i> 346: 1458\u20131459, 2014","DOI":"10.1126\/science.aaa3814"},{"key":"72","unstructured":"72) Zahnow CA, Topper M, Stone M, et al.: Inhibitors of DNA methylation, histone deacetylation, and histone demethylation: a perfect combination for cancer therapy. <i>Adv Cancer Res<\/i> 130: 55\u2013111, 2016"},{"key":"73","doi-asserted-by":"crossref","unstructured":"73) Song Y, Wu F, Wu J: Targeting histone methylation for cancer therapy: enzymes, inhibitors, biological activity and perspectives. <i>J Hematol Oncol<\/i> 9: 49, 2016","DOI":"10.1186\/s13045-016-0279-9"},{"key":"74","doi-asserted-by":"crossref","unstructured":"74) Popovic R, Licht JD: Emerging epigenetic targets and therapies in cancer medicine. <i>Cancer Discov<\/i> 2: 405\u2013413, 2012","DOI":"10.1158\/2159-8290.CD-12-0076"},{"key":"75","doi-asserted-by":"crossref","unstructured":"75) McGrath J, Trojer P: Targeting histone lysine methylation in cancer. <i>Pharmacol Ther<\/i> 150: 1\u201322, 2015","DOI":"10.1016\/j.pharmthera.2015.01.002"},{"key":"76","doi-asserted-by":"crossref","unstructured":"76) Liu Y, Liu K, Qin S, Xu C, Min J: Epigenetic targets and drug discovery: part 1: histone methylation. <i>Pharmacol Ther<\/i> 143: 275\u2013294, 2014","DOI":"10.1016\/j.pharmthera.2014.03.007"},{"key":"77","doi-asserted-by":"crossref","unstructured":"77) Liu K, Liu Y, Lau JL, Min J: Epigenetic targets and drug discovery Part 2: Histone demethylation and DNA methylation. <i>Pharmacol Ther<\/i> 151: 121\u2013140, 2015","DOI":"10.1016\/j.pharmthera.2015.04.001"},{"key":"78","doi-asserted-by":"crossref","unstructured":"78) Kruidenier L, Chung CW, Cheng Z, et al.: A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response. <i>Nature<\/i> 488: 404\u2013408, 2012","DOI":"10.1038\/nature11262"},{"key":"79","doi-asserted-by":"crossref","unstructured":"79) Ramaswamy V, Remke M, Taylor MD: An epigenetic therapy for diffuse intrinsic pontine gliomas. <i>Nat Med<\/i> 20: 1378\u20131379, 2014","DOI":"10.1038\/nm.3769"},{"key":"80","doi-asserted-by":"crossref","unstructured":"80) Morales La Madrid A, Hashizume R, Kieran MW: Future Clinical Trials in DIPG: Bringing Epigenetics to the Clinic. <i>Front Oncol<\/i> 5: 148, 2015","DOI":"10.3389\/fonc.2015.00148"},{"key":"81","doi-asserted-by":"crossref","unstructured":"81) Lulla RR, Saratsis AM, Hashizume R: Mutations in chromatin machinery and pediatric high-grade glioma. <i>Sci Adv<\/i> 2: e1501354, 2016","DOI":"10.1126\/sciadv.1501354"},{"key":"82","doi-asserted-by":"crossref","unstructured":"82) Van Vlierberghe P, Ambesi-Impiombato A, Perez-Garcia A, et al.: ETV6 mutations in early immature human T cell leukemias. <i>J Exp Med<\/i> 208: 2571\u20132579, 2011","DOI":"10.1084\/jem.20112239"},{"key":"83","doi-asserted-by":"crossref","unstructured":"83) Valk PJ, Verhaak RG, Beijen MA, et al.: Prognostically useful gene-expression profiles in acute myeloid leukemia. <i>N Engl J Med<\/i> 350: 1617\u20131628, 2004","DOI":"10.1056\/NEJMoa040465"},{"key":"84","doi-asserted-by":"crossref","unstructured":"84) Mohammad F, Weissmann S, Leblanc B, et al.: EZH2 is a potential therapeutic target for H3K27M-mutant pediatric gliomas. <i>Nat Med<\/i> 23: 483\u2013492, 2017","DOI":"10.1038\/nm.4293"},{"key":"85","doi-asserted-by":"crossref","unstructured":"85) Ellis L, Pan Y, Smyth GK, et al.: Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma. <i>Clin Cancer Res<\/i> 14: 4500\u20134510, 2008","DOI":"10.1158\/1078-0432.CCR-07-4262"},{"key":"86","doi-asserted-by":"crossref","unstructured":"86) Grasso CS, Tang Y, Truffaux N, et al.: Functionally defined therapeutic targets in diffuse intrinsic pontine glioma. <i>Nat Med<\/i> 21: 555\u2013559, 2015","DOI":"10.1158\/1535-7163.TARG-15-LB-B06"},{"key":"87","doi-asserted-by":"crossref","unstructured":"87) Hennika T, Hu G, Olaciregui NG, et al.: Pre-clinical study of panobinostat in xenograft and genetically engineered murine diffuse intrinsic pontine glioma models. <i>PLoS One<\/i> 12: e0169485, 2017","DOI":"10.1371\/journal.pone.0169485"},{"key":"88","doi-asserted-by":"crossref","unstructured":"88) Filippakopoulos P, Qi J, Picaud S, et al.: Selective inhibition of BET bromodomains. <i>Nature<\/i> 468: 1067\u20131073, 2010","DOI":"10.1038\/nature09504"},{"key":"89","doi-asserted-by":"crossref","unstructured":"89) Delmore JE, Issa GC, Lemieux ME, et al.: BET bromodomain inhibition as a therapeutic strategy to target c-Myc. <i>Cell<\/i> 146: 904\u2013917, 2011","DOI":"10.1016\/j.cell.2011.08.017"},{"key":"90","doi-asserted-by":"crossref","unstructured":"90) Nicodeme E, Jeffrey KL, Schaefer U, et al.: Suppression of inflammation by a synthetic histone mimic. <i>Nature<\/i> 468: 1119\u20131123, 2010","DOI":"10.1038\/nature09589"},{"key":"91","doi-asserted-by":"crossref","unstructured":"91) Dawson MA, Prinjha RK, Dittmann A, et al.: Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. <i>Nature<\/i> 478: 529\u2013533, 2011","DOI":"10.1038\/nature10509"},{"key":"92","doi-asserted-by":"crossref","unstructured":"92) Mirguet O, Gosmini R, Toum J, et al.: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains. <i>J Med Chem<\/i> 56: 7501\u20137515, 2013","DOI":"10.1021\/jm401088k"},{"key":"93","doi-asserted-by":"crossref","unstructured":"93) Berenguer-Daiz\u00e9 C, Astorgues-Xerri L, Odore E, et al.: OTX015 (MK-8628), a novel BET inhibitor, displays in vitro and in vivo antitumor effects alone and in combination with conventional therapies in glioblastoma models. <i>Int J Cancer<\/i> 139: 2047\u20132055, 2016","DOI":"10.1002\/ijc.30256"},{"key":"94","doi-asserted-by":"crossref","unstructured":"94) Puissant A, Frumm SM, Alexe G, et al.: Targeting MYCN in neuroblastoma by BET bromodomain inhibition. <i>Cancer Discov<\/i> 3: 308\u2013323, 2013","DOI":"10.1158\/2159-8290.CD-12-0418"},{"key":"95","doi-asserted-by":"crossref","unstructured":"95) Lov\u00e9n J, Hoke HA, Lin CY, et al.: Selective inhibition of tumor oncogenes by disruption of super-enhancers. <i>Cell<\/i> 153: 320\u2013334, 2013","DOI":"10.1016\/j.cell.2013.03.036"},{"key":"96","doi-asserted-by":"crossref","unstructured":"96) Pastori C, Daniel M, Penas C, et al.: BET bromodomain proteins are required for glioblastoma cell proliferation. <i>Epigenetics<\/i> 9: 611\u2013620, 2014","DOI":"10.4161\/epi.27906"},{"key":"97","doi-asserted-by":"crossref","unstructured":"97) Cheng Z, Gong Y, Ma Y, et al.: Inhibition of BET bromodomain targets genetically diverse glioblastoma. <i>Clin Cancer Res<\/i> 19: 1748\u20131759, 2013","DOI":"10.1158\/1078-0432.CCR-12-3066"},{"key":"98","doi-asserted-by":"crossref","unstructured":"98) Pastori C, Kapranov P, Penas C, et al.: The bromodomain protein BRD4 controls HOTAIR, a long noncoding RNA essential for glioblastoma proliferation. <i>Proc Natl Acad Sci USA<\/i> 112: 8326\u20138331, 2015","DOI":"10.1073\/pnas.1424220112"}],"container-title":["Neurologia medico-chirurgica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/nmc\/57\/7\/57_ra.2017-0018\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T05:44:56Z","timestamp":1659073496000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/nmc\/57\/7\/57_ra.2017-0018\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"references-count":98,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.2176\/nmc.ra.2017-0018","relation":{},"ISSN":["0470-8105","1349-8029"],"issn-type":[{"value":"0470-8105","type":"print"},{"value":"1349-8029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017]]}}}